Prognostic value of thoracic FDG PET imaging after treatment for non-small cell lung cancer.


Journal Article

OBJECTIVE: We determined the prognostic value of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) for patients with treated lung cancer. MATERIALS AND METHODS: We examined patients who underwent FDG PET after first-line treatment for non-small cell lung cancer. FDG PET results were correlated with survival rates to determine whether FDG PET findings were predictive of outcomes. RESULTS: After initial therapy, 113 patients with non-small cell lung cancer underwent FDG PET. One hundred patients had positive FDG PET results and a median survival of 12 months (95% confidence interval, 9.2-15.4). Thirteen patients had negative FDG PET results, and 11 (85%) of these patients are still living at a median follow-up of 34 months. The difference in survival for patients with positive and negative FDG PET results was statistically significant (p = 0.002). CONCLUSION: FDG PET has prognostic value and strongly correlates with survival rates of patients with treated lung cancer. Patients with positive FDG PET results have a significantly worse prognosis than patients with negative results. Additionally, FDG PET may be helpful in guiding therapeutic treatments.

Full Text

Duke Authors

Cited Authors

  • Patz, EF; Connolly, J; Herndon, J

Published Date

  • March 2000

Published In

Volume / Issue

  • 174 / 3

Start / End Page

  • 769 - 774

PubMed ID

  • 10701623

Pubmed Central ID

  • 10701623

International Standard Serial Number (ISSN)

  • 0361-803X

Digital Object Identifier (DOI)

  • 10.2214/ajr.174.3.1740769


  • eng

Conference Location

  • United States